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INTRODUCTION
Dialysis patients have a high incidence of cardiovascular
morbidity and mortality (1, 2). Vascular calcification (VC)
in hemodialysis (HD) patients was associated with increased
stiffness of the artery and has already known to be related to
cardiovascular disease and cardiovascular mortality (3-5). The
simple VC score of plain radiographic films of the pelvis and
hands was independently associated with coronary artery dis-
ease and peripheral arterial disease at the end of the follow-up
(6). There are two types of VC on the plain radiograph, arte-
rial medial calcification and arterial intimal calcification which
has irregular and patchy distribution. The presence of medi-
al artery calcifications on the plain radiograph which is more
common in dialysis patients than in the general population,
is a powerful and independent prognostic marker for all-cause
and cardiovascular mortality in chronic HD patients (7, 8).
Typical linear railroad-track type (angiography like) calcifica-
tions on the plain radiograph that outline the vessel walls are
considered as medial artery calcification which is differenti-
ated from intimal calcifications (7). Medial artery calcifica-
tion of dorsalis pedis artery on the plain radiography of feet
is also one of peripheral artery vascular calcifications such as
vascular calcification of hands. 
Maintenance dialysis patients have a reverse association with
some traditional risk factors; body mass index (BMI), hyper-
cholesterolaemia and hypertension reduced the relative risk
of death in epidemiological studies (9-11). In fact, dialysis
patients have specific non-traditional risk factors; inflamma-
tion, malnutrition, oxidative stress, and abnormal mineral
metabolism are other important risk factors for vascular dis-
ease (12). In general, oxidized low density lipoprotein (ox-
LDL) cholesterol is closely associated with the inflammatory
process in vascular atherosclerotic lesions (13, 14) and inflam-
matory marker, C-reactive protein (CRP), is a stronger predic-
tor of cardiovascular events than low density lipoprotein (LDL)
cholesterol (15). Plasminogen activator inhibitor-1 (PAI-1)
is also linked to vascular inflammation and atherosclerosis (16).
Thus, CRP, PAI-1 and ox-LDL have a high possibility of rela-
tion with VC which is risk factor of cardiovascular morbidi-
ty and mortality in dialysis patients. The present study was
designed to find factors related with medial artery calcifica-
tion on the plain radiography of feet by comparing CRP,
PAI-1 and lipid profile including ox-LDL and to elucidate
associations among these factors in HD patients. 
MATERIALS AND METHODS 
Patients
We recruited a total of 48 HD patients (male: 24 patients,
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Associations between Oxidized LDL to LDL Ratio, HDL and Vascular
Calcification in the Feet of Hemodialysis Patients
Cardiovascular mortality is associated with vascular calcification (VC) in hemodial-
ysis (HD) patients. The present study was designed to find factors related with medi-
al artery calcification on the plain radiography of feet by comparing C-reactive pro-
tein (CRP), plasminogen activator inhibitor type 1 (PAI-1) and lipid profile including
oxidized low density lipoprotein (ox-LDL) and to elucidate associations among these
factors in HD patients. Forty-eight HD patients were recruited for this study. VC in
the feet was detected in 18 patients (37.5%) among total patients and 12 patients
(85.7%) among diabetic patients. Diabetes, cardiovascular disease (CVD), pulse
pressure, ox-LDL/LDL were higher and high density lipoprotein (HDL) was lower in
patients with VC than in patients without VC. Negative associations were found be-
tween HDL and CRP, PAI-1. PAI-1 had positive association with ox-LDL/LDL. His-
tory of CVD was the only determinant of vascular calcification on the plain radiog-
raphy of feet. Ox-LDL/LDL, HDL, CRP, and PAI-1 were closely related with one anoth-
er in HD patients. History of CVD is the most important factor associated with the
presence of VC and low HDL and relatively high oxidized LDL/LDL ratio may affect
VC formation on the plain radiography in the feet of HD patients.
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Accepted : 1 December 2008diabetes: 14 patients) from Dong-A University dialysis cen-
ter and a neighboring local dialysis center. Patients with HD
duration of less than 6 months, patients with a catheter as
vascular access, history of active infection within 3 months,
malignancy and chronic liver disease were excluded. The mean
age of the patients was 56.3±11.5 yr and the mean duration
on HD was 77.1±54.1 months. Enrolled HD patients receiv-
ed regular HD thrice weekly. Bicarbonate-based dialysate and
polysulphone dialyzers (Fresenius, Bad Homburg, Germany)
were used. Informed consent was obtained in accordance with
the guidelines set forth by the Declaration of Helsinki. We
defined medial artery calcification on the plain radiograph
of feet as vascular calcification. We reviewed medical history
and records by chart review and interview. Coronary artery
disease (CAD), cerebrovascular accident and peripheral artery
disease (PAD) were defined as cardiovascular disease (CVD).
We defined CAD based on the records of myocardial SPECT
scan, echocardiography or coronary angiography. Patients with
a history of lower extremity amputation caused by PAD, steno-
sis of peripheral artery on the color doppler ultrasonography
or present ulceration and necrosis of the foot were defined as
PAD. We reviewed current medications and checked blood
pressure of the enrolled patients in the sitting position before
hemodialysis.
Radiography of both feet
Standard radiographs of both feet were taken to determine
VC. AXIOM Aristos MX/VX (SIEMENS, Erlangen, Ger-
many) radiographic equipment with digital imaging system
was used and exposure condition was approximately 45-50
kVp (4 mAs).
Calcifications that outline the dorsalis pedis artery on the
plain radiograph were shown as typical linear railroad-track
form like angiography (Fig. 1). VC of this form indicates medi-
al artery calcification. One nephrologist and one radiologist
individually decided VC of the dorsalis pedis artery on the
plain radiograph without information of patients. Consen-
sus was reached on the interpretation of all radiographs.
Laboratory measurements
Routine laboratory tests such as hemoglobin, blood urea
nitrogen (BUN), creatinine, albumin, calcium, phosphate,
intact parathyroid hormone (iPTH), CRP and lipid profile
were obtained using fasting blood samples. Normalized pro-
tein catabolic rate (nPCR), fractional clearance of urea as a func-
tion of its distribution volume (Kt/V urea) and BMI were also
determined. HbA1c was checked in diabetic patients. PAI-1
was measured by ASSERACHROM
� PAI-1 kit (Diagnosti-
ca stago Inc, NJ, U.S.A.), oxidized LDL (Mercodia, Uppsala,
Sweden) and anti-oxidized LDL antibody (oLAB; Biomedi-
ca, Vienna, Austria) was measured by using a commercially
available enzyme linked immunosorbent assay kit.
Prehemodialysis blood samples were obtained from the arte-
riovenous fistula or graft in HD patients. Samples were imme-
diately placed on ice. Plasma and serum were promptly sep-
arated by centrifugation and stored at -70℃until assayed.
Statistics
Data are presented as mean±S.D. except iPTH which is
expressed as mean±S.E. Comparisons of unpaired data were
performed using Mann-Whitney U test. Correlation analy-
ses were examined by using Spearman test. Differences in
frequency were tested using chi-square analysis. Significant
variables identified by univariate analysis were entered into
a binary logistic regression analysis to identify variables asso-
ciated with vascular calcification. p values less than 0.05 were
considered significant. All statistical calculations were per-
formed with SPSS software, version 12.0 (SPSS Inc, Chica-
go, IL, U.S.A.).
RESULTS
Comparison of data according to vascular calcification
Data are summarized in Table 1 and Table 2. The preva-
lence rate of VC was 37.5% in these HD patients. VC on
the plain radiography of feet was found to be significantly
more common in diabetic patients than in non-diabetic
patients (66.7% vs. 6.7%, p<0.001). Diabetic HD patients
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Fig. 1. Standard radiograph of foot shows definite vascular calci-
fications on the course of dorsalis pedis artery. High density that
outline the dorsalis pedis artery on the plain radiograph was shown
as typical linear railroad-track form like angiography indicates vas-
cular media calcification of dorsalis pedis artery (arrow).showed significantly shorter HD duration than non-diabet-
ic HD patients (34.5±36.0 vs. 95.0±50.6 months, p<
0.001). HD duration was also shorter in patients with VC
than in patients without VC. Age, gender, BMI, smoking
history, systolic blood pressure, diastolic blood pressure and
calcium loads by taking phosphate binder were not signifi-
cantly different among groups with VC and without VC.
History of coronary artery disease and cardiovascular disease
were more frequent and pulse pressure was higher in
patients with VC than in patients without VC. The percent
of patients who had been taking aspirin was significantly
higher in patients with VC than in patients without VC.
The percent of patients who had been taking angiotensin
converting enzyme inhibitors, angiotensin receptor blockers,
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BMI, body mass index; HD, hemodialysis; DM, diabetes mellitus; CAD,
history of coronary artery disease; CVD, history of cardiovascular disease;
AV, arteriovenous; SBP, systolic blood pressure; DBP, diastolic blood
pressure; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; CCB, calcium channel blocker.
Calcification (-) Calcification (+) p value
N3 0 1 8 -
Age (yr) 54.4±12.9 59.4±7.8 0.166
Male/female 14/16 10/8 0.555
BMI (kg/m
2) 20.2±2.0 20.9±2.8 0.521
Smoking history (%) 10 (33.3) 7 (38.9) 0.466
HD duration (months) 93.6±52.7 50.9±46.6 0.007
DM (%) 2 (6.7) 12 (66.7) <0.001
CAD (%) 1 (3.3) 11 (61.1) <0.001
CVD (%) 2 (6.7) 15 (83.3) <0.001
AV graft (%) 2 (6.7) 4 (22.2) 0.039
SBP (mmHg) 147.8±15.4 155.9±14.4 0.132
DBP (mmHg) 76.8±14.2 71.8±13.3 0.248
Pulse pressure 71.0±17.9 84.1±14.3 0.008
Calcium loads (mg/day) 2,603±1,399 2,673±1,496 0.964
ACEI (%) 10 (33.8) 10 (55.6) 0.135
ARB (%) 11 (36.7) 10 (55.6) 0.206
CCB (%) 16 (53.3) 12 (66.7) 0.369
Statin (%) 1(3.3) 0 (0.0) 0.321
Aspirin (%) 9 (30) 14 (77.8) 0.002
Vitamin D (%) 10 (33.3) 3 (16.7) 0.217
Table 1. Comparison of clinical characteristics between patients
with vascular calcification and without vascular calcification (Data
are expressed as mean±S.D. iPTH is expressed as mean±S.E.)
Ca, calcium; P, phosphate; CaXP, Calcium phosphate product; iPTH,
intact parathyroid hormone; BUN, blood urea nitrogen; HDL, high den-
sity lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; Ox-
LDL, oxidized LDL; oLAB, anti-oxidized LDL antibody; PAI-1, plasmino-
gen activator inhibitor 1; CRP, C-reactive protein; nPCR, normalized pro-
tein catabolic rate; Kt/V urea, fractional clearance of urea as a function
of its distribution volume.
Calcification (-) Calcification (+) p value
Ca (mg/dL) 8.8±0.8 8.8±0.5 0.495
P (mg/dL) 5.7±1.0 5.5±1.6 0.798
CaXP (mg/dL)
2 49.5±12.1 48.2±13.5 0.709
iPTH (pg/mL) 196.5±81.2 159.3±45.8 0.427
BUN (mg/dL) 74.3±14.0 64.0±1.5 0.129
Creatinine (mg/dL) 11.9±1.9 9.8±47.22 0.099
Albumin (g/dL) 4.0±0.3 4.1±0.3 0.419
Cholesterol (mg/dL) 161.6±34.0 150.7±28.2 0.237
Triglyceride (mg/dL) 105.0±46.9 102.6±56.1 0.798
HDL (mg/dL) 44.8±10.1 38.2±6.6 0.029
LDL (mg/dL) 88.8±30.0 78.8±21.1 0.250
Ox-LDL (U/L) 50.7±11.4 56.0±15.2 0.358
Ox-LDL/LDL 0.60±0.15 0.73±0.15 0.022
oLAB (mU/mL) 416.9±287.1 341.5±307.3 0.131
PAI-1 (ng/mL) 145.5±75.6 179.4±72.5 0.088
CRP (mg/dL) 0.29±0.46 0.53±0.53 0.045
HbA1c 6.5±0.4 7.2±1.4 0.641
nPCR 1.17±0.23 0.99±0.30 0.064
Kt/V urea 1.34±0.17 1.28±0.20 0.374
Table 2. Comparison of laboratory results between patients with
vascular calcification and without vascular calcification
Fig. 2. Correlation between CRP, PAI-1 and HDL in hemodialysis patients.
CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor 1; HDL, high density lipoprotein cholesterol.
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(94.4% vs. 93.3%), statin and vitamin D was not significant-
ly different among groups with VC and without VC (Table 1).
Patients with VC had much more arteriovenous graft as a
vascular access compared to patients without VC. Patients
with VC showed significantly higher oxidized LDL to LDL
ratio and CRP levels, lower high density lipoprotein (HDL)
cholesterol than patients without VC. Calcium, phosphate,
iPTH, BUN, creatinine, serum albumin, total cholesterol,
triglyceride, LDL, ox-LDL, anti-oxidized LDL antibody
(oLAB), PAI-1, HbA1c, nPCR and Kt/V urea were not sig-
nificantly different among groups with VC and without VC
(Table 2). 
Correlation between ox-LDL/LDL, HDL, CRP, and PAI-1
A negative association was found between ox-LDL and oLAB
(r=-0.426, p=0.003). Negative associations were found between
HDL and PAI-1(r=-0.375, p=0.009), CRP (r=-0.336, p=0.023)
(Fig. 2). A positive association was found between PAI-1 and
ox-LDL to LDL ratio (r=0.305, p=0.016).
Logistic regression analysis according to vascular
calcification
Significant predictors detecting the presence of VC were
diabetes mellitus, history of cardiovascular disease, HD dura-
tion, pulse pressure, HDL and ox-LDL to LDL ratio in uni-
variate analysis. History of cardiovascular disease was the only
independent factor associated with the presence of VC (odds
ratio: 55.71 and 95% confidence interval: 2.75-1130.46,
p=0.009) by multivariate analysis including age and gender
(Table 3).
DISCUSSION
VC in dialysis patients has been related to diabetes, CVD and
increased stiffness of artery (3-5, 8, 17, 18). In our study, his-
tory of diabetes, CVD and high pulse pressure were related
with the presence of medial artery calcification on the plain
radiography of feet, but history of CVD was the only inde-
pendent factor associated with the presence of VC. Thus we
can consider evaluation of CVD if there is angiography like
VC of dorsalis pedis artery on the plain radiography of feet
in HD patients. A recent report mentioned that coexistence
of coronary artery calcification (CAC) and peripheral artery
calcification was common particularly in chronic kidney disease
patients with diabetes, although VC detected by plain
radiograph of foot was not an adequate marker for identify-
ing patients with CAC (19). They checked a standardized
plain radiograph of the left foot to determine if there was
any calcification of the dorsalis pedis artery, not medial
artery calcification.
Ox-LDL is known as a marker of atherosclerosis in HD
patients (20). High levels of ox-LDL are associated with cal-
cification of the aortic valve in patients with aortic valve
stenosis (21). However, ox-LDL was not involved in coronary
artery calcification in HD patients (22). Ox-LDL was not
significantly different, but ox-LDL to LDL ratio was signifi-
cantly different among groups with VC and without VC in
our study. Ox-LDL to LDL ratio, an accurate estimation of
in vivo LDL oxidation (23), indicates an environment of
oxidative stress in HD patients with relatively low LDL lev-
els. Thus, we suggest that the formation of medial artery
calcification on the plain radiograph of feet may be affected
by oxidative stress. In other aspect, if there are medial artery
calcifications of feet, they reflect high oxidative stress condi-
tion.
The higher titer of anti-oxidized LDL antibody in females
and young persons had a negative association with atheroscle-
rosis (24) and anti-oxidized LDL antibody was independently
inversely associated with arterial wall thickness in HD patients
(25). Ox-LDL had a reverse relationship with anti-oxidized
LDL antibody in our HD patients. This result supports the
anti-atherogenic role of anti-oxidized LDL antibody. But there
is no evidence that anti-oxidized LDL antibody is related with
VC in our study; it requires further study.
HDL was significantly associated with calcification in extra-
coronary arteries evaluated by electron beam computed tomog-
raphy (26). Furthermore, low HDL levels were associated with
rapid progression of coronary artery calcification determined
by electron-beam computed tomography in HD patients (27).
HD patients with VC exhibited significantly lower HDL lev-
els than HD patients without VC in this study. Thus, low
HDL which is common in dialysis patients may play a role
in the formation of VC on the plain radiograph of feet.
HDL has anti-oxidant and anti-inflammatory properties.
The anti-oxidant effect of HDL was shown by inhibition of
LDL oxidation in healthy young men (28). In our study there
was no association between HDL and ox-LDL but a negative
association was found between HDL and CRP as well as HDL
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OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; CVD, his-
tory of cardiovascular disease; HD, hemodialysis; HDL, high density li-
poprotein cholesterol; Ox-LDL, oxidized LDL; LDL, low density lipopro-
tein cholesterol.
Variables OR (95% CI) p value
Age 1.03 (0.94-1.14) 0.513
Gender 0.91 (0.07-11.65) 0.940
DM 2.39 (0.07-80.69) 0.628
CVD 55.71(2.75-1,130.46) 0.009
HD duration (months) 1.01 (0.97-1.04) 0.688
Pulse pressure 1.03 (0.95-1.12) 0.445
HDL (mg/dL) 0.96 (0.80-1.16) 0.657
Ox-LDL/LDL 2,261.57 (0.62-8,312,558.7) 0.065
Table 3. Determinants of vascular calcification on the plain radio-
graphy of feet by multivariate analysis including age and genderand PAI-1, which are important markers of inflammation
and atherosclerosis. PAI-1 levels are elevated in dialysis patients
with developing atheromatous cardiovascular disease associ-
ated with oxidative stress and inflammation (29). A recent
report showed that PAI-1 was related with ox-LDL and inflam-
mation in HD patients (30). PAI-1 had a positive relation with
ox-LDL to LDL ratio in our study. This result supports that
PAI-1 may be linked to oxidative stress. CRP levels were ele-
vated in our HD patients with VC compared to HD patients
without VC. Krasniak A et al. (22) reported that CRP was
related with coronary artery calcification in HD patients, al-
though CRP was not an independent factor. Finally, these
observations suggest that ox-LDL/LDL, HDL, PAI-1, and
CRP may be indirectly cross- linked in HD patients who have
conditions of oxidative stress and inflammation.
This cross-sectional study has some limitations. The dura-
tion of dialysis correlates with calcification in the peripheral
arteries (8). But our study showed that HD duration was short-
er in patients with VC than in patients without VC. This
result is affected by diabetic HD patients, who had shorter
HD duration and frequent VC in our study. And cardiovas-
cular calcification was more prevalent in those receiving cal-
cium containing phosphate binders (31). But our cross-sec-
tional study showed that calcium, phosphate, calcium and
phosphate product, iPTH, phosphate binder and vitamin D
medication was not different among groups with VC and
without VC. Thus prospective study will be needed to eval-
uate the effect of hyperphosphatemia and phosphate binder
in HD patients without vascular calcification.
In conclusion, Ox-LDL/LDL, HDL, CRP, and PAI-1 were
closely related with one another in HD patients. History of
CVD is the most important factor associated with the pres-
ence of VC in the feet and low HDL and relatively high oxi-
dized LDL/LDL ratio may affect VC formation on the plain
radiography in the feet of HD patients. 
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